- Company
- Improving access to Lenvima and its later-line treatment
- by Eo, Yun-Ho May 25, 2020 06:27am
- 1 The Korean pharmaceutical industry is keeping a close eye on the Cancer Deliberation Committee’s June meeting to discuss the coverage on later-line treatment following Lenvima treating liver cancer. The pharmaceutical industry sources reported the Cancer Deliberation Committee could talk about extending the access of patient with hepatoce
- Company
- Erectile dysfunction treatment market suffered from COVID-19
- by An, Kyung-Jin May 25, 2020 06:26am
- The well-established domestic erectile dysfunction treatment market was stagnant. As the sales of large products sold by Hanmi Pharm, Chong Kun Dang, and Pfizer decreased, the overall market size was lowered. According to the analysis, the market for erectile dysfunction treatment, which has a relatively low disease severity, has been suff
- Company
- Pfizer stopped Duavive due to quality problems
- by Kim, Jin-Gu May 25, 2020 06:26am
- Pfizer Pharmaceuticals voluntarily recovers its own menopausal treatment drug Duavive. This is based on the identification of potential quality problems in the results of self-investigation. On the 21st, Pfizer Pharmaceuticals requested each drug distributor to discontinue certain lot numbers of Duavive 0.45mg / 20mg folowing as ▲DC5278
- Company
- Alvogen Korea secures domestic rights for Seroquel
- by An, Kyung-Jin May 25, 2020 06:26am
- Alvogen Korea took over the domestic rights of the drug 'Seroquel' (Quetiapine), a treatment for schizophrenia. Alvogen Korea announced on the 21st that it has signed an exclusive distribution and marketing contract for 'Seroquel' and 'Seroquel XR' with Luye Pharma in China, and approval of the domestic license has been completed. Seroq
- Policy
- Virtual academic conferences consider e-booth as alternative
- by Kim, Jung-Ju May 25, 2020 06:26am
- Academic conferences in Korea are going through changes as many of academic events around the world are either canceled or postponed amid COVID-19 outbreak. While the medical experts predict the outbreak would not end anytime soon, a number of medical academia have either convened virtual conference or are planning on one to replace th
- Company
- Qsymia puts a brake on Saxenda in Q1 obesity drug market
- by An, Kyung-Jin May 22, 2020 06:17am
- The Korean obesity treatment market has fluctuated significantly in the year. The so-called ‘Gangnam Diet Injection,’ Saxenda lost its solid market leadership and now shares the top spot with Qsymia. Saxenda’s sales has halved as soon as Qsymia entered the market and took over a significant part of it. On May 20, pharmaceutical marke
- Company
- MOHW-KRPIA meeting canceled as confirmed COVID-19 reported
- by Eo, Yun-Ho May 22, 2020 06:16am
- A confirmed case of COVID-19 was reported from Twin City Namsan building that houses the office of Korean Research-based Pharmaceutical Industry Association (KRPIA). Accordingly, the meeting originally scheduled on May 21 to convene Ministry of Health and Welfare (MOHW) Division of Pharmaceutical Benefits officials and KRPIA and multinat
- Policy
- Concerta OROS'll be moved overseas to complete registration
- by Lee, Tak-Sun May 22, 2020 06:16am
- Janssen Korea, which decided to operate a domestic factory by 2021, is in a hurry to convert imports of licensed items. Following the transition to an overseas manufactory earlier this year, six items have been changed in permission, and in June, the manufacturing plant of the ADHD treatment, Concerta OROS ER will also be moved overseas to
- InterView
- Improvement is urgent for many generic drugs
- by Lee, Tak-Sun May 22, 2020 06:16am
- After the Regulatory Reform Committee recommended the withdrawal of the joint bioequivalence test restriction policy in April, the Ministry of Food and Drug Safety's first reaction was to respect the recommendation to withdraw, but said that there was still a problem with the issue of generic restructuring. In a briefing with reporters on
- Policy
- COVID-19 vaccines/quarantine items road map details released
- by Kim, Jung-Ju May 22, 2020 06:16am
- The quarantine authorities will release a detailed road map for 'COVID-19' vaccine and quarantine products next week. Regarding vaccines, the area of greatest interest, R & D of nucleic acid vaccines, such as those under development by Moderna, is also actively being conducted in Korea. Kwon Joon-wook, deputy general manager of the Central
